# What 262 Trials Say Together

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/what-262-trials-say-together

> 262 trials, 99,791 people, 19 drugs, every result graded. Three of its findings cut against how this field is described, starting with the fact that the drug with the mortality evidence is not the one that takes off the most weight.

## Key points

- Tirzepatide −14.9% and CagriSema −14.8% lead on weight at one year.
- Subcutaneous semaglutide is the ONLY drug with a mortality signal (RR 0.81), and it is fifth on weight.
- That signal comes largely from trials in already-high-risk people.
- Across 43 trials and 45,663 people, NO drug improved quality of life beyond the threshold patients notice.
- Tirzepatide loses the most fat (25.7%) AND the most lean mass (8.3%).
- Retatrutide and the other emerging agents are graded VERY LOW to LOW certainty.

The BMJ pooled **262 randomized trials covering 99,791 people and 19 drugs**, graded the certainty of every result, and produced the best available answer to [which obesity drug is best](https://glpwatchdog.org/research/best-injection-for-weight-loss).[1] Three of its findings cut against how this field is usually described. One is that the drug with the strongest evidence for keeping people alive is not the one that takes off the most weight.

## Weight loss at one year

*Mean difference in body weight at one year against lifestyle modification alone, moderate to high certainty.[1]*

| Drug | Weight difference | 95% CI |
| --- | --- | --- |
| Tirzepatide | −14.9% | −16.0 to −13.9 |
| Cagrilintide–semaglutide (CagriSema) | −14.8% | −16.9 to −12.7 |
| **Oral semaglutide** | **−10.9%** | −12.7 to −9.1 |
| Orforglipron | −9.9% | −12.4 to −7.5 |
| **Subcutaneous semaglutide** | **−9.8%** | −10.6 to −9.1 |
| Phentermine–topiramate | −8.1% | −9.7 to −6.5 |

> **If that subcutaneous semaglutide figure looks wrong, it is measuring something different from the number you are thinking of.** The famous 14.9% is the average loss on the drug in a single placebo-controlled trial.[2] This is a pooled estimate against *lifestyle modification*, across every eligible trial and dose, over a standardized one-year horizon. Both are correct answers to different questions, and only one of them lets you line nineteen drugs up beside each other.

The newer agents (ecnoglutide, [mazdutide](https://glpwatchdog.org/research/mazdutide-what-the-evidence-shows), retatrutide) may reach 13.1% to 14.6%, but at **very low to low certainty**, which is the analysis’s way of saying the evidence is thin enough that these numbers could move substantially. Carry that grading into any conversation about [drugs you cannot yet be prescribed](https://glpwatchdog.org/research/retatrutide-phase-3-and-the-gray-market).

## The drug with the outcome evidence is not the strongest one

Weight is a proxy. What people want is to live longer and avoid heart attacks. On those outcomes the ranking reorders completely.

*Hard outcomes. Only agents with a credible signal are listed.[1]*

| Outcome | Drug | Risk ratio (95% CI) |
| --- | --- | --- |
| All-cause mortality | **Subcutaneous semaglutide only** | 0.81 (0.72–0.93) |
| Myocardial infarction | **Subcutaneous semaglutide only** | 0.72 (0.61–0.85) |
| Heart failure | Subcutaneous semaglutide | 0.43 (0.21–0.84) |
| Heart failure | Tirzepatide | 0.49 (0.27–0.88) |
| Kidney failure | None convincingly | — |

> The only drug associated with fewer deaths is fifth on the weight-loss table.

> **One caveat has to travel with those two rows.** The mortality and heart attack estimates are largely informed by [cardiovascular outcome trials](https://glpwatchdog.org/research/lists/top-glp1-cardiovascular-studies) conducted in people who were already at high risk. They describe what the drug does for someone with established cardiovascular disease. They do not establish that a healthy person taking it for weight will live longer.

The reason the ranking reorders is not mysterious: the drug that has been studied longest in the sickest people has the outcome data. Tirzepatide may well show the same or better in time. Right now it has not, and “loses more weight” and “prevents more deaths” are separate claims requiring separate evidence.

## No drug cleared the quality-of-life threshold

Across 43 trials and 45,663 participants, **no drug improved quality of life beyond [the established threshold for a difference patients notice](https://glpwatchdog.org/research/real-and-below-the-threshold)**. Every mean difference came in under 5 points on scales where 10 is the minimally important difference.

That is a pooled average, and single questionnaires can read higher. A 2026 analysis of six tirzepatide trials found physical function 10.10 points better than placebo on the weight-specific IWQOL-Lite-CT, but only 2.26 points better on the general SF-36, with results so inconsistent between trials that its authors urged caution.[4] In SURMOUNT-4, people who stayed on tirzepatide finished 11.1 points ahead of those switched to placebo on the IWQOL-Lite-CT total score.[5] That trial measures what is lost on stopping, in people who had already tolerated the drug. These are different scales and designs, so they qualify the review without overturning it.

That is a striking result for treatments whose entire promise is feeling better, and it independently confirms something we reported from the head-to-head trial, where the mental component of a quality-of-life survey did not significantly improve in either arm over 72 weeks (see [the mental health score that did not move](https://glpwatchdog.org/research/the-mental-health-score-that-did-not-move)). One trial finding that is easy to dismiss. Forty-three trials finding it is not.

It does not mean nobody feels better. It means that across the assembled evidence, the average improvement on validated instruments falls below what researchers had agreed in advance would count as noticeable. It is also a claim about *general* instruments. In heart failure, where a disease-specific symptom score was used, both drugs tested produced improvements patients would notice (see [the one place people felt better](https://glpwatchdog.org/research/the-one-place-people-felt-better)).

## Bigger effects, bigger costs

The analysis’s own conclusion is that larger benefits are generally accompanied by greater harms and more discontinuation. The specifics bear that out.

- **Stopping because of side effects** was highest with orforglipron, naltrexone–bupropion and liraglutide, as well as phentermine–topiramate, CagriSema and oral semaglutide (risk ratios 1.9 to 4.2).
- **Gastrointestinal events** were most increased with naltrexone–bupropion, oral semaglutide, orforglipron and tirzepatide (risk ratios 3.1 to 4.2).
- **Fatigue** rose with naltrexone–bupropion (risk ratio 8.9, an extra 331 people per 1,000 over a year), orforglipron (3.4, 100 more per 1,000) and CagriSema (3.2, 92 more per 1,000). Treat the first figure with caution: the Contrave label, pooling its placebo-controlled trials, lists fatigue in 4.0% on the drug and 3.4% on placebo, and the review’s abstract does not explain the gap.[3]
- **Tirzepatide cut fat mass by the largest margin (25.7%), and lean mass by the largest margin too (8.3%).**

Two of those deserve a second look. Orforglipron appears on both the discontinuation and gastrointestinal lists. That matches its own head-to-head trial against oral semaglutide, which found roughly double the dropouts (see [the first pill-versus-pill trial](https://glpwatchdog.org/research/the-first-pill-versus-pill-trial)). And the tirzepatide body composition row is the muscle question quantified: the drug that removes the most fat also removes the most lean tissue, which is what [lean mass on a drug versus dieting](https://glpwatchdog.org/research/lean-mass-drug-versus-dieting) examines.

## What the subgroups did not show

One quiet finding is useful because it is negative. Subgroup analyses across drug dosages and patient characteristics **did not identify credible differences in relative treatment effects**. The one exception was that longer trials showed larger weight reductions for subcutaneous semaglutide.

In plain terms, nothing in the evidence suggests that particular kinds of patient respond differently in a way anyone can currently predict. That is the same conclusion reached from a different direction by the genetics work, where real predictors exist and are too small to act on (see [the genetics are real, and small](https://glpwatchdog.org/research/the-genetics-are-real-and-small)).

## Frequently asked questions

### Which obesity drug produces the most weight loss?

Tirzepatide, at 14.9% below lifestyle modification alone at one year, closely followed by cagrilintide-semaglutide at 14.8%. Both estimates carry moderate to high certainty in the 262-trial analysis.

### Why is subcutaneous semaglutide only 9.8% here?

Because this is a pooled estimate against lifestyle modification, across all eligible trials and doses over a standardized year. The familiar 14.9% is the average loss on the drug in one placebo-controlled trial. Both are correct answers to different questions.

### Which drug has evidence for preventing death?

Subcutaneous semaglutide, and only it, with a risk ratio of 0.81 for all-cause mortality and 0.72 for myocardial infarction. Those estimates come largely from trials in people already at high cardiovascular risk, so they do not establish the same benefit for a healthy person taking it for weight.

### Do these drugs improve quality of life?

Across 43 trials and 45,663 participants, no drug improved quality of life beyond the threshold agreed in advance as noticeable to patients. Every mean difference was under 5 points where 10 is the minimally important difference. Weight-specific questionnaires in tirzepatide trials have shown larger differences, of about 10 points, on a different scale.

### Which drugs are hardest to tolerate?

Discontinuation for adverse events was highest with orforglipron, naltrexone-bupropion and liraglutide, as well as phentermine-topiramate, CagriSema and oral semaglutide. Fatigue rose most with naltrexone-bupropion in this analysis, at an extra 331 people per 1,000 over a year, though the Contrave label's pooled trials list fatigue at only 4.0% on the drug against 3.4% on placebo.

### What about muscle loss?

Tirzepatide cut fat mass by the largest margin, 25.7%, and lean mass by the largest margin too, 8.3%.

## References

1. Nong K, Shi Q, Xie X, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026. PMID: 42419792. https://pubmed.ncbi.nlm.nih.gov/42419792/
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
3. Nalpropion Pharmaceuticals CONTRAVE (naltrexone and bupropion) extended-release tablets: prescribing information (section 6.1). DailyMed, U.S. National Library of Medicine. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b
4. Schmidt PHS, de Souza VSN, Machado LG, et al. Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis. Diabetes Obes Metab. 2026. PMID: 41705736. DOI: 10.1111/dom.70529. https://pubmed.ncbi.nlm.nih.gov/41705736/
5. Gibble TH, Cao D, Murphy M, et al. Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4. Obesity (Silver Spring). 2025. PMID: 40903801. DOI: 10.1002/oby.70011. https://pubmed.ncbi.nlm.nih.gov/40903801/

---

Cite as: GLP Watchdog, Nora Bissett, "What 262 Trials Say Together", published 2026-08-20, updated 2026-11-02. https://glpwatchdog.org/research/what-262-trials-say-together

Canonical HTML page: https://glpwatchdog.org/research/what-262-trials-say-together

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
